Literature DB >> 32323189

Should we monitor the direct oral anticoagulants?

Robert Diep1, David Garcia2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32323189      PMCID： PMC7433889          DOI： 10.1007/s11239-020-02119-2

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  14 in total

1.  Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.

Authors:  Erin A Bohula; Robert P Giugliano; Christian T Ruff; Julia F Kuder; Sabina A Murphy; Elliott M Antman; Eugene Braunwald
Journal:  Circulation       Date:  2016-07-05       Impact factor: 29.690

Review 2.  Clinical Management of Pharmacokinetic Drug Interactions with Direct Oral Anticoagulants (DOACs).

Authors:  Megan C Herink; Yan F Zhuo; Craig D Williams; Thomas G DeLoughery
Journal:  Drugs       Date:  2019-10       Impact factor: 9.546

3.  Real-world variability in dabigatran levels in patients with atrial fibrillation.

Authors:  N C Chan; M Coppens; J Hirsh; J S Ginsberg; J I Weitz; T Vanassche; J D Douketis; S Schulman; J W Eikelboom
Journal:  J Thromb Haemost       Date:  2015-01-28       Impact factor: 5.824

4.  The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).

Authors:  Paul A Reilly; Thorsten Lehr; Sebastian Haertter; Stuart J Connolly; Salim Yusuf; John W Eikelboom; Michael D Ezekowitz; Gerhard Nehmiz; Susan Wang; Lars Wallentin
Journal:  J Am Coll Cardiol       Date:  2013-09-27       Impact factor: 24.094

5.  Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery.

Authors:  Dino Kröll; Guido Stirnimann; Andreas Vogt; Desirée Lin Lee Lai; Yves Michael Borbély; Julia Altmeier; Sabine Schädelin; Daniel Candinas; Lorenzo Alberio; Philipp C Nett
Journal:  Br J Clin Pharmacol       Date:  2017-03-09       Impact factor: 4.335

6.  Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.

Authors:  Christian T Ruff; Robert P Giugliano; Eugene Braunwald; David A Morrow; Sabina A Murphy; Julia F Kuder; Naveen Deenadayalu; Petr Jarolim; Joshua Betcher; Minggao Shi; Karen Brown; Indravadan Patel; Michele Mercuri; Elliott M Antman
Journal:  Lancet       Date:  2015-03-11       Impact factor: 79.321

7.  Pharmacogenetics of dabigatran etexilate interindividual variability.

Authors:  Claudia Dimatteo; Giovanna D'Andrea; Gennaro Vecchione; Oriana Paoletti; Filomena Cappucci; Giovanni Luca Tiscia; Matteo Buono; Elvira Grandone; Sophie Testa; Maurizio Margaglione
Journal:  Thromb Res       Date:  2016-05-26       Impact factor: 3.944

Review 8.  Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH.

Authors:  K Martin; J Beyer-Westendorf; B L Davidson; M V Huisman; P M Sandset; S Moll
Journal:  J Thromb Haemost       Date:  2016-04-27       Impact factor: 5.824

9.  Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring.

Authors:  Wolfgang Mueck; Stephan Schwers; Jan Stampfuss
Journal:  Thromb J       Date:  2013-06-28

10.  Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants.

Authors:  Sophie Testa; Cristina Legnani; Emilia Antonucci; Oriana Paoletti; Claudia Dellanoce; Benilde Cosmi; Vittorio Pengo; Daniela Poli; Rossella Morandini; Roberto Testa; Armando Tripodi; Gualtiero Palareti
Journal:  J Thromb Haemost       Date:  2019-05-26       Impact factor: 5.824
View more
  2 in total

Review 1.  An algorithmic approach to gastrointestinal bleeding in patients receiving antithrombotic agents.

Authors:  Amir Sadeghi; Mohammad Reza Zali; Hamid Mohaghegh Shalmani; Pardis Ketabi Moghadam; Mohsen Rajabnia Chenari; Mohammad Ali Karimi; Sina Salari; Hamid Asadzadeh-Aghdaei
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2020

2.  Long-Term Anticoagulation in Secondary Ischemic Stroke Prevention: The Prospective Multicenter RESTAIC Registry.

Authors:  Raquel Gutiérrez-Zúñiga; Ricardo Rigual; Gabriel Torres-Iglesias; Sara Sánchez-Velasco; María Alonso de Leciñana; Jaime Masjuan; Rodrigo Álvarez Velasco; Inmaculada Navas; Laura Izquierdo-Esteban; José Fernández-Ferro; Jorge Rodríguez-Pardo; Gerardo Ruiz-Ares; Gustavo Zapata-Wainberg; Blanca Fuentes; Exuperio Díez-Tejedor
Journal:  Front Neurol       Date:  2020-10-19       Impact factor: 4.003
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.